June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Mesenchymal stem cells-derived interleukin-11 inhibits activation and proliferation of T cells
Author Affiliations & Notes
  • Aastha Singh
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Sharad Mittal
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • WonKyung Cho
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Yilin Guan
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Elsayed Elbasiony
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Sunil Chauhan
    Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Aastha Singh None; Sharad Mittal None; WonKyung Cho None; Yilin Guan None; Elsayed Elbasiony None; Sunil Chauhan None
  • Footnotes
    Support  NIH/NEI-R01EY024602
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3261 – A0296. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Aastha Singh, Sharad Mittal, WonKyung Cho, Yilin Guan, Elsayed Elbasiony, Sunil Chauhan; Mesenchymal stem cells-derived interleukin-11 inhibits activation and proliferation of T cells. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3261 – A0296.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Uncontrolled T cell activation can result pathological conditions including autoimmunity and graft rejections. Our group has previously shown that mesenchymal stem cells (MSCs) inhibit activation of innate immune cells including neutrophils and macrophages. Here, we investigate whether MSCs regulate T cell responses by secreting interleukin-11 (IL-11).

Methods : Human bone-marrow derived MSCs (hMSCs) were purchased and phenotypically characterized for their expression of CD45- CD34- CD73+ CD90+. CD4+ CD25- T cells (purity: >95%) were magnetically sorted from human peripheral blood mononuclear cells for the MSC-T cell co-culture assays. Expression and secretion of IL-11 by hMSCs were evaluated using real-time PCR and ELISA, respectively. Expression of IL-11 receptor was confirmed in activated CD4+ CD25- T cells using flow cytometry. CD4+ CD25- T cells stimulated with anti-CD3/CD28 beads (1:1 ratio) were co-cultured with MSCs at 1:1 ratio for 24 hours (for early activation) and 66 hours (for proliferation) in the presence and absence of hIL-11 neutralizing antibody (20 µg/ml). Early T cell activation was assessed by evaluating expression of CD40L and CD69 (Median Fluorescence intensity; MFI) using flow cytometry. For proliferation, CD4+ CD25- T cells were stained with CFSE prior to co-culture and their proliferation was quantified by measuring CFSE dilution via flow cytometry.

Results : hMSCs constitutively express high levels of IL-11 at both mRNA and protein levels. Naïve CD4+ CD25<font size="1">-</font> T cells showed the expression of IL-11 receptor, which was upregulated by 2-fold following CD3/CD28 stimulation. hMSCs significantly suppressed early activation of naive T cells, as indicated by an approximate 70% reduction in expression of both CD69 (p=0.025) and CD40L (p=0.011). This MSC mediated reduction in early T cell activation was not observed following the neutralization of IL-11. Furthermore, our CFSE dilution assay demonstrated that hMSCs significantly prevented the proliferation of CD4+ CD25<font size="1">-</font>T cells (p=0.006); however, this MSC-mediated suppression of proliferation was abrogated following IL-11 neutralization.

Conclusions : IL-11 secretion by human mesenchymal stem cells is critical for inhibition of early T cell activation and proliferation.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×